LOFACIMIG
UNII L55HB62LXD

Substance Identification & Data

This profile provides standardized clinical and technical data for Lofacimig, uniquely identified by the FDA Unique Ingredient Identifier (UNII) L55HB62LXD.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2857858-76-3 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

L55HB62LXD

CAS Registry Number

2857858-76-3

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

LOFACIMIG

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C211782

National Cancer Institute reference terminology for clinical and research data.

INN ID

13117

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Lofacimig. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

LOFACIMIG

Common Names & Synonyms

H-GAMMA1 HEAVY CHAIN VH-VH-G1(H-CH2-CH3) (1-493) (VH ANTI-F11 APPLE 2 DOMAIN (CAMELUS DROMEDARIUS IGHV3S45*01 (86.6%)/HOMO SAPIENS IGHV3-66*01 (83.5%) -(IGHD) -IGHJ5*02 (100%), CDR-IMGT (9.7.23) (26-34.52-58.97-119)) (1-130) -3-MER (GLYCYL-ALANYL-PROLYL) LINKER (131-133) -(VH ANTI-F11 APPLE 3 DOMAIN (CAMELUS DROMEDARIUS IGHV3S72*01 (81.2%)/HOMO SAPIENS IGHV3-64*04 (79.4%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT (8.7.20) (159-166.184-190.229-248)) (134-259) -2-MER (GLYCYL-SERYL) LINKER (260-261) -HOMO SAPIENS IGHG1*01 H-CH2-CH3-CHS G1M17,1 CH3 D12, L14, G1V37 H S5 (HINGE 1-15 C5>S(266) (262-276), CH2 (277-386), CH3 D12 (402), L14 (404) (387-491), CHS (492-493)) (262-493)); DIMER (272-272':275-275')-BISDISULFIDE, PRODUCED IN CHINESE HAMSTER OVARY (CHO) CELLS, CELL LINE CHO-K1, GLYCOFORM ALFA

IMMUNOGLOBULIN, BIPARATROPIC, ANTI-(HUMAN COAGULATION FACTOR XI APPLE 2 DOMAIN) (HUMAN-LAMA GLAMA MONOCLONAL KN060 SINGLE-DOMAIN VHH FRAGMENT) FUSION PROTEIN WITH PEPTIDE LINKER (GAP) FUSION PROTEIN WITH IMMUNOGLOBULIN ANTI-(HUMAN COAGULATION FACTOR XI APPLE 3 DOMAIN) (HUMAN-LAMA GLAMA MONOCLONAL KN060 SINGLE-DOMAIN VHH FRAGMENT) FUSION PROTEIN WITH PEPTIDE LINKER(GS) FUSION PROTEIN WITH IMMUNOGLOBULIN G1 (5-SERINE) (HUMAN .GAMMA.1-CHAIN C REGION C-TERMINAL FRAGMENT), DIMER

LOFACIMIG [INN]

ONLY-HEAVY-CHAIN IMMUNOGLOBULIN VH-VH-G1(H-CH2-CH3) DIMER, ANTI-(HOMO SAPIENS F11 (COAGULATION FACTOR XI, FXI, PLASMA THROMBOPLASTIN ANTECEDENT, PTA) APPLE 2 DOMAIN) AND ANTI-(HOMO SAPIENS F11 (COAGULATION FACTOR XI, FXI, PLASMA THROMBOPLASTIN ANTECEDENT, PTA) APPLE 3 DOMAIN) HUMANIZED MONOCLONAL ANTIBODY, BISPECIFIC, TETRAVALENT

External Clinical & Regulatory Resources

Previous UNIIL55D9W33FY

Next UNIIL55K56E9N0